Tech Company Financing Transactions
Stargazer Pharmaceuticals Funding Round
Canaan Partners, Novo Ventures and Pontifax AgTech participated in a $57 million Series A venture round for Stargazer Pharmaceuticals. The round was announced on 11/10/2020.
Transaction Overview
Company Name
Announced On
11/10/2020
Transaction Type
Venture Equity
Amount
$57,000,000
Round
Series A
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Clarendon St. 45th Floor Mailbox 30
Boston, MA 02215
USA
Boston, MA 02215
USA
Phone
Email Address
Not Recorded
Overview
Stargazer Pharmaceuticals, Inc., is a Boston-based biopharmaceutical drug development company launched in 2018 with a focus on rare diseases of the eye, and an initial focus on Stargardt Disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gary Sternberg
Chief Marketing Officer
Houman Hemmati
Chief Operating Officer
Silvia Ragno
Browse more venture capital transactions:
Prev: 11/10/2020: Demoflow venture capital transaction
Next: 11/10/2020: Prometheus Biosciences venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC transactions reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs